No Data
No Data
Frontier Biotech 2024 Semi-Annual Report
Frontier Biotech 2024 Semi-Annual Report Summary
Frontline Bio (688221.SH) released its performance for the first half of the year, with a net loss of 0.16 billion yuan.
Frontier Biotech (688221.SH) released its 2024 semi-annual report, with a revenue of 5 billion yuan during the reporting period...
Frontier Biotech (688221.SH): gradually launching pilot clinics for the prevention of exposure to Ecnotin in Shanghai and other areas.
On July 8th, Gelunhui reported that Front Bio(688221.SH) stated on the investor interaction platform that currently there are 0.1-0.15 million new HIV infections in China each year, more than 90% of which are transmitted through sexual activity. MSM (men who have sex with men) and high-risk heterosexual groups are both high-risk groups that urgently need to raise awareness of prevention. Timely PEP measures can help reduce HIV transmission. In the future, as the awareness of prevention and medication knowledge for high-risk groups improves after exposure, the market for HIV post-exposure prophylaxis medication will gradually open up. Ekkoning, as a long-acting anti-HIV injection, is a new drug in the field of AIDS prevention.
Frontier Biotechnologies Inc.'s (SHSE:688221) Biggest Owners Are Individual Investors Who Got Richer After Stock Soared 18% Last Week
About 160 million restricted shares of Frontier Biotech (688221.SH) will be listed for trading starting on July 1st.
The Frontier Biotech (688221.SH) announced that the restricted shares to be listed this time are part of the restricted shares publicly issued for the first time by the company, involving 8 shareholders of restricted shares, with a corresponding stock quantity of approximately 160 million shares, accounting for 42.7% of the total share capital of the company. This restricted shares will be listed and traded starting from July 1, 2024.
No Data
No Data